Peptide therapeutics market: forecast and analysis 2015-2025
This article discusses the state of the peptide therapeutics market, with special emphasis on the application is managing metabolic disorders and cancers. The wide-ranging application of peptides in numerous disease indications has bolstered the global peptide therapeutics market. Pharma companies are increasing their research and development spending to gain a stronghold in a market which was valued at $17.5 Bn in 2015. Along with offering a detailed analysis of the peptide therapeutics market, this article offers market figures on the basis of disease indication and 10-year region-wise forecast in the three largest markets – North America, Western Europe, and Asia Pacific excluding Japan (APEJ).
Peptides are growing in prominence in the pharmaceutical research and development (R&D) sector, owing to their wide-ranging applications in the effective management of a number of diseases. Peptide therapeutics are easy to produce as compared to protein-based biopharmaceuticals, offering a substantial cost advantage to pharma companies.
Over the last two decades or so, innovation in development of peptides, such as multifunctional and cell penetrating peptides, has opened up a plethora of opportunities for use of peptides in therapy. Development of peptide therapeutics is also growing on account of evolution of hybrid technology – which combines both solid and liquid synthesis of naturally occurring peptides. Peptide conjugation and modification strategies offer the potential to unlock the full potential of peptides for therapeutic benefit.
GLOBAL PEPTIDE THERAPEUTICS MARKET
The global peptide therapeutics market was valued at $17.5 billion in 2015. It is expected to increase at a compound annual growth rate (CAGR) of 10.3% during 2015-2025 and total US$ 47 billion in revenues by 2025.
The key macroeconomic factors driving the ...